iTeos Therapeutics, Inc.·4

Jun 25, 8:00 PM ET

Gall Matthew 4

4 · iTeos Therapeutics, Inc. · Filed Jun 25, 2021

Insider Transaction Report

Form 4
Period: 2021-06-24
Gall Matthew
Chief Financial Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2021-06-24+24,00024,000 total
    Exercise: $23.19Exp: 2031-06-24Common Stock (24,000 underlying)
Footnotes (1)
  • [F1]This stock option shall vest over 4 years, with 25% vesting on June 24, 2022 and thereafter in equal monthly installments over the next 36 months subject to the Reporting Person's continued service to the Issuer.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION